title: The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects.
abstract: BACKGROUND
  In Japan, dipeptidyl peptidase 4 (DPP4) inhibitors have become standard therapeutic agents for type 2 diabetes, and numbers of patients receiving insulin therapy combined with DPP4 inhibitors, which is a highly effective regimen, are increasing.
  
  
  METHODS
  In this study, we evaluated the efficacy of vildagliptin administered at the dose of 100 mg twice daily in 57 patients with type 2 diabetes already receiving insulin treatment.
  
  
  RESULTS
  The 36 patients who simply received add-on vildagliptin showed a 0.6% decrease in HbA1c levels, despite a marked insulin dose reduction, mainly bolus insulin, of approximately 8.3 units. In addition, body mass index exhibited a significant negative correlation with the efficacy of vildagliptin, i.e., ΔHbA1c. On the other hand, the 21 patients switched from 50 mg of sitagliptin to vildagliptin showed HbA1c decreases approaching 0.7%.
  
  
  CONCLUSIONS
  Taking into consideration that twice-daily oral vildagliptin has already been reported to be advantageous in reducing postprandial hyperglycemia, this drug was suggested to be more effective in reducing HbA1c than sitagliptin under conditions in which it is used as a supplement to basal insulin, as in this study.
authors.affiliation: Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan ; Division of Internal Medicine, Ogawa Red Cross Hospital, 1525, Ogawa, Ogawa-machi, Hiki, Saitama 355-0397, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ito
authors.affiliation: Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Inoue
authors.affiliation: Division of Internal Medicine, Ogawa Red Cross Hospital, 1525, Ogawa, Ogawa-machi, Hiki, Saitama 355-0397, Japan.
authors.forename: Kimie
authors.initials: K
authors.lastname: Kaneko
authors.affiliation: Satsuki Medical Clinic, 1-471, Ogawa, Ogawa-machi, Hiki, Saitama 355-0397, Japan.
authors.forename: Morifumi
authors.initials: M
authors.lastname: Yanagisawa
authors.affiliation: Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Sumita
authors.affiliation: Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ikegami
authors.affiliation: Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan.
authors.forename: Takuya
authors.initials: T
authors.lastname: Awata
authors.affiliation: Third Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishida
authors.affiliation: Division of Endocrinology and Diabetes, Saitama Medical University, 38, Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan.
authors.forename: Shigehiro
authors.initials: S
authors.lastname: Katayama
authors.affiliation: Third Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, Japan.
authors.forename: Kouichi
authors.initials: K
authors.lastname: Inukai
keywords: Insulin therapy; Sitagliptin; Type 2 diabetes; Vildagliptin